Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology to maximize global clinical impact and patient access, announces that MAT2203, an oral LNC formulation of amphotericin B (AMB), will be featured in two oral presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.
The two presentations are as follows:
“We are delighted that clinical evidence supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections will be presented at this prestigious conference,” said Theresa Matkovits, PhD, Chief Development Officer of Matinas BioPharma. “The efficacy of amphotericin B is well established, but this fungicidal drug is typically administered selectively only to patients with severe disease because of its toxicity, which significantly limits its use. MAT2203 reduces systemic toxicity by directing amphotericin B to targeted cells at sites of infection, supporting a favorable safety profile relative to IV-administered AMB with the additional benefit of oral administration. The data to be presented at ECCMID, from both our EnACT Phase 2 trial and a compelling compassionate use case, support our strategy of developing the ideal antifungal agent for the treatment of a variety of invasive fungal infections while also potentially having a dramatic pharmacoeconomic impact on the cost of treating these deadly diseases.
“Imprtantly, success with MAT2203 gives us confidence that our platform technology can be applied beyond small molecules to a multitude of treatment modalities that alter the genetic mechanisms that underlie disease, an area we view as the future of medicine,” added Dr. Matkovits. “We believe that our delivery platform holds promise for the targeted delivery of gene therapy, providing Matinas with the opportunity to develop robust internal and partnered drug development candidates.”
About Matinas BioPharma
Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery for both small molecules and larger, more complex molecules such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral) positions Matinas’ LNC technology potentially to become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors. For more information, please visit www.matinasbiopharma.com.
LHA Investor Relations